GB202407194D0 - - Google Patents

Info

Publication number
GB202407194D0
GB202407194D0 GBGB2407194.6A GB202407194A GB202407194D0 GB 202407194 D0 GB202407194 D0 GB 202407194D0 GB 202407194 A GB202407194 A GB 202407194A GB 202407194 D0 GB202407194 D0 GB 202407194D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2407194.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Priority to GBGB2407194.6A priority Critical patent/GB202407194D0/en
Publication of GB202407194D0 publication Critical patent/GB202407194D0/en
Priority to EP25176581.4A priority patent/EP4652989A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2407194.6A 2024-05-21 2024-05-21 Ceased GB202407194D0 (https=)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2407194.6A GB202407194D0 (https=) 2024-05-21 2024-05-21
EP25176581.4A EP4652989A1 (en) 2024-05-21 2025-05-15 Coated tenofovir alafenamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2407194.6A GB202407194D0 (https=) 2024-05-21 2024-05-21

Publications (1)

Publication Number Publication Date
GB202407194D0 true GB202407194D0 (https=) 2024-07-03

Family

ID=92932474

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2407194.6A Ceased GB202407194D0 (https=) 2024-05-21 2024-05-21

Country Status (2)

Country Link
EP (1) EP4652989A1 (https=)
GB (1) GB202407194D0 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007016A (es) * 2003-01-14 2005-09-12 Gilead Sciences Inc Composiciones y metodos para terapia antiviral de combinacion.
KR20160042475A (ko) * 2014-10-09 2016-04-20 주식회사 네비팜 테노포비어 함유 의약조성물 및 그의 제조방법
CN109568284B (zh) * 2018-12-29 2020-04-24 广东中润药物研发有限公司 一种替诺福韦艾拉酚胺肠溶片及其制备方法
CN115400091A (zh) * 2021-04-29 2022-11-29 四川海思科制药有限公司 一种酒石酸丙酚替诺福韦片药物组合物及其制备方法

Also Published As

Publication number Publication date
EP4652989A1 (en) 2025-11-26

Similar Documents

Publication Publication Date Title
CN308404055S (https=)
CN308404099S (https=)
CN308404266S (https=)
CN308407220S (https=)
CN308407366S (https=)
CN308407678S (https=)
CN308407741S (https=)
CN308407748S (https=)
CN308407756S (https=)
CN308407842S (https=)
CN308407915S (https=)
CN308407949S (https=)
CN308407953S (https=)
CN308408342S (https=)
CN308408366S (https=)
CN308408496S (https=)
CN308408503S (https=)
CN308408707S (https=)
CN308410475S (https=)
CN308410513S (https=)
CN308410646S (https=)
CN308412184S (https=)
CN308412827S (https=)
CN308413327S (https=)
CN308413419S (https=)

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)